Xu, Jian-Ming <br/><br/>
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Dec 2003 
 - 442-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0344-5704 
<br/><br/><label>Standard No.: </label>10.1007/s00280-003-0687-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Colonic Neoplasms--pathology<br/>DNA Adducts--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Evaluation, Preclinical<br/>Gefitinib<br/>HT29 Cells<br/>Humans<br/>Inhibitory Concentration 50<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Precipitin Tests<br/>Quinazolines--administration & dosage